Exelixis to Present at the Morgan Stanley Global Healthcare Conference on September 13
-- Presentation to be webcast on
www.exelixis.com --
Exelixis, Inc. (NASDAQ:EXEL) today announced that Michael M. Morrissey, Ph.D., the company’s president and chief executive
officer, will provide an overview of the company at the Morgan Stanley Global Healthcare Conference taking place September 12-14 in
New York, NY. The Exelixis presentation is scheduled for 9:10 AM EDT/6:10 AM PDT on Tuesday, September 13, 2016.
The presentation will be webcast live and may be accessed via the Event Calendar page under Investors & Media at www.exelixis.com. Please connect to the company’s website at least 15 minutes prior to the presentation to
ensure adequate time for any software download that may be require to listen to the webcast. A replay will also be available at the
same location for 14 days.
About Exelixis
Exelixis, Inc. (Nasdaq: EXEL) is a biopharmaceutical company committed to the discovery, development and commercialization of
new medicines with the potential to improve care and outcomes for people with cancer. Since its founding in 1994, three medicines
discovered at Exelixis have progressed through clinical development to receive regulatory approval. Currently, Exelixis is focused
on advancing cabozantinib, an inhibitor of multiple tyrosine kinases including MET, AXL and VEGF receptors, which has shown
clinical anti-tumor activity in more than 20 forms of cancer and is the subject of a broad clinical development program. Two
separate formulations of cabozantinib have received regulatory approval to treat certain forms of kidney and thyroid cancer and are
marketed for those purposes as CABOMETYX™ tablets (U.S.) and COMETRIQ® capsules (U.S. and EU), respectively. Another
Exelixis-discovered compound, COTELLIC® (cobimetinib), a selective inhibitor of MEK, has been approved in major
territories including the United States and European Union, and is being evaluated for further potential indications by Roche and
Genentech (a member of the Roche Group) under a collaboration with Exelixis. For more information on Exelixis, please visit
www.exelixis.com or follow @ExelixisInc on Twitter.
Investors Contact:
Exelixis, Inc.
Susan Hubbard, 650-837-8194
Investor Relations and Public Affairs
shubbard@exelixis.com
or
Media Contact:
For Exelixis, Inc.
Hal Mackins, 415-994-0040
hal@torchcommunications.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20160831006434/en/